人工智能、健康和医疗保健的今天和明天:JAMA人工智能峰会报告。

JAMA Pub Date : 2025-10-13 DOI:10.1001/jama.2025.18490
Derek C Angus,Rohan Khera,Tracy Lieu,Vincent Liu,Faraz S Ahmad,Brian Anderson,Sivasubramanium V Bhavani,Andrew Bindman,Troyen Brennan,Leo Anthony Celi,Frederick Chen,I Glenn Cohen,Alastair Denniston,Sanjay Desai,Peter Embí,Aldo Faisal,Kadija Ferryman,Jackie Gerhart,Marielle Gross,Tina Hernandez-Boussard,Michael Howell,Kevin Johnson,Kristine Lee,Xiaoxuan Liu,Kimberly Lomis,Alex John London,Christopher A Longhurst,Ken Mandl,Elizabeth McGlynn,Michelle M Mello,Fatima Munoz,Lucila Ohno-Machado,David Ouyang,Roy Perlis,Adam Phillips,David Rhew,Joseph S Ross,Suchi Saria,Lee Schwamm,Christopher W Seymour,Nigam H Shah,Rashmee Shah,Karandeep Singh,Matthew Solomon,Kathryn Spates,Kayte Spector-Bagdady,Tommy Wang,Judy Wawira Gichoya,James Weinstein,Jenna Wiens,Kirsten Bibbins-Domingo,
{"title":"人工智能、健康和医疗保健的今天和明天:JAMA人工智能峰会报告。","authors":"Derek C Angus,Rohan Khera,Tracy Lieu,Vincent Liu,Faraz S Ahmad,Brian Anderson,Sivasubramanium V Bhavani,Andrew Bindman,Troyen Brennan,Leo Anthony Celi,Frederick Chen,I Glenn Cohen,Alastair Denniston,Sanjay Desai,Peter Embí,Aldo Faisal,Kadija Ferryman,Jackie Gerhart,Marielle Gross,Tina Hernandez-Boussard,Michael Howell,Kevin Johnson,Kristine Lee,Xiaoxuan Liu,Kimberly Lomis,Alex John London,Christopher A Longhurst,Ken Mandl,Elizabeth McGlynn,Michelle M Mello,Fatima Munoz,Lucila Ohno-Machado,David Ouyang,Roy Perlis,Adam Phillips,David Rhew,Joseph S Ross,Suchi Saria,Lee Schwamm,Christopher W Seymour,Nigam H Shah,Rashmee Shah,Karandeep Singh,Matthew Solomon,Kathryn Spates,Kayte Spector-Bagdady,Tommy Wang,Judy Wawira Gichoya,James Weinstein,Jenna Wiens,Kirsten Bibbins-Domingo, ","doi":"10.1001/jama.2025.18490","DOIUrl":null,"url":null,"abstract":"Importance\r\nArtificial intelligence (AI) is changing health and health care on an unprecedented scale. Though the potential benefits are massive, so are the risks. The JAMA Summit on AI discussed how health and health care AI should be developed, evaluated, regulated, disseminated, and monitored.\r\n\r\nObservations\r\nHealth and health care AI is wide-ranging, including clinical tools (eg, sepsis alerts or diabetic retinopathy screening software), technologies used by individuals with health concerns (eg, mobile health apps), tools used by health care systems to improve business operations (eg, revenue cycle management or scheduling), and hybrid tools supporting both business operations (eg, documentation and billing) and clinical activities (eg, suggesting diagnoses or treatment plans). Many AI tools are already widely adopted, especially for medical imaging, mobile health, health care business operations, and hybrid functions like scribing outpatient visits. All these tools can have important health effects (good or bad), but these effects are often not quantified because evaluations are extremely challenging or not required, in part because many are outside the US Food and Drug Administration's regulatory oversight. A major challenge in evaluation is that a tool's effects are highly dependent on the human-computer interface, user training, and setting in which the tool is used. Numerous efforts lay out standards for the responsible use of AI, but most focus on monitoring for safety (eg, detection of model hallucinations) or institutional compliance with various process measures, and do not address effectiveness (ie, demonstration of improved outcomes). Ensuring AI is deployed equitably and in a manner that improves health outcomes or, if improving efficiency of health care delivery, does so safely, requires progress in 4 areas. First, multistakeholder engagement throughout the total product life cycle is needed. This effort would include greater partnership of end users with developers in initial tool creation and greater partnership of developers, regulators, and health care systems in the evaluation of tools as they are deployed. Second, measurement tools for evaluation and monitoring should be developed and disseminated. Beyond proposed monitoring and certification initiatives, this will require new methods and expertise to allow health care systems to conduct or participate in rapid, efficient, and robust evaluations of effectiveness. The third priority is creation of a nationally representative data infrastructure and learning environment to support the generation of generalizable knowledge about health effects of AI tools across different settings. Fourth, an incentive structure should be promoted, using market forces and policy levers, to drive these changes.\r\n\r\nConclusions and Relevance\r\nAI will disrupt every part of health and health care delivery in the coming years. Given the many long-standing problems in health care, this disruption represents an incredible opportunity. However, the odds that this disruption will improve health for all will depend heavily on the creation of an ecosystem capable of rapid, efficient, robust, and generalizable knowledge about the consequences of these tools on health.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"91 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"AI, Health, and Health Care Today and Tomorrow: The JAMA Summit Report on Artificial Intelligence.\",\"authors\":\"Derek C Angus,Rohan Khera,Tracy Lieu,Vincent Liu,Faraz S Ahmad,Brian Anderson,Sivasubramanium V Bhavani,Andrew Bindman,Troyen Brennan,Leo Anthony Celi,Frederick Chen,I Glenn Cohen,Alastair Denniston,Sanjay Desai,Peter Embí,Aldo Faisal,Kadija Ferryman,Jackie Gerhart,Marielle Gross,Tina Hernandez-Boussard,Michael Howell,Kevin Johnson,Kristine Lee,Xiaoxuan Liu,Kimberly Lomis,Alex John London,Christopher A Longhurst,Ken Mandl,Elizabeth McGlynn,Michelle M Mello,Fatima Munoz,Lucila Ohno-Machado,David Ouyang,Roy Perlis,Adam Phillips,David Rhew,Joseph S Ross,Suchi Saria,Lee Schwamm,Christopher W Seymour,Nigam H Shah,Rashmee Shah,Karandeep Singh,Matthew Solomon,Kathryn Spates,Kayte Spector-Bagdady,Tommy Wang,Judy Wawira Gichoya,James Weinstein,Jenna Wiens,Kirsten Bibbins-Domingo, \",\"doi\":\"10.1001/jama.2025.18490\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Importance\\r\\nArtificial intelligence (AI) is changing health and health care on an unprecedented scale. Though the potential benefits are massive, so are the risks. The JAMA Summit on AI discussed how health and health care AI should be developed, evaluated, regulated, disseminated, and monitored.\\r\\n\\r\\nObservations\\r\\nHealth and health care AI is wide-ranging, including clinical tools (eg, sepsis alerts or diabetic retinopathy screening software), technologies used by individuals with health concerns (eg, mobile health apps), tools used by health care systems to improve business operations (eg, revenue cycle management or scheduling), and hybrid tools supporting both business operations (eg, documentation and billing) and clinical activities (eg, suggesting diagnoses or treatment plans). Many AI tools are already widely adopted, especially for medical imaging, mobile health, health care business operations, and hybrid functions like scribing outpatient visits. All these tools can have important health effects (good or bad), but these effects are often not quantified because evaluations are extremely challenging or not required, in part because many are outside the US Food and Drug Administration's regulatory oversight. A major challenge in evaluation is that a tool's effects are highly dependent on the human-computer interface, user training, and setting in which the tool is used. Numerous efforts lay out standards for the responsible use of AI, but most focus on monitoring for safety (eg, detection of model hallucinations) or institutional compliance with various process measures, and do not address effectiveness (ie, demonstration of improved outcomes). Ensuring AI is deployed equitably and in a manner that improves health outcomes or, if improving efficiency of health care delivery, does so safely, requires progress in 4 areas. First, multistakeholder engagement throughout the total product life cycle is needed. This effort would include greater partnership of end users with developers in initial tool creation and greater partnership of developers, regulators, and health care systems in the evaluation of tools as they are deployed. Second, measurement tools for evaluation and monitoring should be developed and disseminated. Beyond proposed monitoring and certification initiatives, this will require new methods and expertise to allow health care systems to conduct or participate in rapid, efficient, and robust evaluations of effectiveness. The third priority is creation of a nationally representative data infrastructure and learning environment to support the generation of generalizable knowledge about health effects of AI tools across different settings. Fourth, an incentive structure should be promoted, using market forces and policy levers, to drive these changes.\\r\\n\\r\\nConclusions and Relevance\\r\\nAI will disrupt every part of health and health care delivery in the coming years. Given the many long-standing problems in health care, this disruption represents an incredible opportunity. However, the odds that this disruption will improve health for all will depend heavily on the creation of an ecosystem capable of rapid, efficient, robust, and generalizable knowledge about the consequences of these tools on health.\",\"PeriodicalId\":518009,\"journal\":{\"name\":\"JAMA\",\"volume\":\"91 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-10-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1001/jama.2025.18490\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/jama.2025.18490","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

人工智能(AI)正在以前所未有的规模改变健康和医疗保健。虽然潜在的好处是巨大的,但风险也是巨大的。美国医学会人工智能峰会讨论了如何开发、评估、监管、传播和监测卫生和卫生保健人工智能。健康和医疗保健人工智能涉及范围广泛,包括临床工具(如败血症警报或糖尿病视网膜病变筛查软件)、有健康问题的个人使用的技术(如移动健康应用程序)、医疗保健系统用于改善业务运营的工具(如收入周期管理或日程安排),以及支持业务运营(如文档和计费)和临床活动(如建议诊断或治疗计划)的混合工具。许多人工智能工具已经被广泛采用,特别是在医学成像、移动健康、医疗保健业务运营以及记录门诊就诊等混合功能方面。所有这些工具都可能对健康产生重要影响(或好或坏),但这些影响往往无法量化,因为评估极具挑战性或不需要,部分原因是许多工具不在美国食品和药物管理局的监管监督范围内。评估中的一个主要挑战是工具的效果高度依赖于人机界面、用户培训和使用工具的环境。许多努力为负责任地使用人工智能制定了标准,但大多数都侧重于安全监测(例如,检测模型幻觉)或对各种过程措施的制度遵从,而不涉及有效性(例如,证明改进的结果)。确保公平地部署人工智能,并以改善健康结果的方式部署,或者在提高卫生保健提供效率的情况下以安全的方式部署人工智能,需要在四个领域取得进展。首先,在整个产品生命周期中需要多利益相关者的参与。这项工作将包括最终用户与开发人员在初始工具创建中的更大合作关系,以及开发人员、监管机构和卫生保健系统在部署工具时对工具进行评估的更大合作关系。第二,应发展和传播评价和监测的衡量工具。除了拟议的监测和认证举措外,这将需要新的方法和专业知识,使卫生保健系统能够进行或参与快速、高效和有力的有效性评估。第三个优先事项是创建具有全国代表性的数据基础设施和学习环境,以支持生成关于人工智能工具在不同环境中的健康影响的可概括知识。第四,应促进激励结构,利用市场力量和政策杠杆来推动这些变化。人工智能将在未来几年颠覆卫生和卫生保健服务的方方面面。鉴于卫生保健领域存在许多长期存在的问题,这种颠覆带来了难得的机遇。然而,这种破坏能否改善所有人的健康,在很大程度上取决于能否建立一个生态系统,使人们对这些工具对健康的影响有快速、有效、健全和可概括的认识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
AI, Health, and Health Care Today and Tomorrow: The JAMA Summit Report on Artificial Intelligence.
Importance Artificial intelligence (AI) is changing health and health care on an unprecedented scale. Though the potential benefits are massive, so are the risks. The JAMA Summit on AI discussed how health and health care AI should be developed, evaluated, regulated, disseminated, and monitored. Observations Health and health care AI is wide-ranging, including clinical tools (eg, sepsis alerts or diabetic retinopathy screening software), technologies used by individuals with health concerns (eg, mobile health apps), tools used by health care systems to improve business operations (eg, revenue cycle management or scheduling), and hybrid tools supporting both business operations (eg, documentation and billing) and clinical activities (eg, suggesting diagnoses or treatment plans). Many AI tools are already widely adopted, especially for medical imaging, mobile health, health care business operations, and hybrid functions like scribing outpatient visits. All these tools can have important health effects (good or bad), but these effects are often not quantified because evaluations are extremely challenging or not required, in part because many are outside the US Food and Drug Administration's regulatory oversight. A major challenge in evaluation is that a tool's effects are highly dependent on the human-computer interface, user training, and setting in which the tool is used. Numerous efforts lay out standards for the responsible use of AI, but most focus on monitoring for safety (eg, detection of model hallucinations) or institutional compliance with various process measures, and do not address effectiveness (ie, demonstration of improved outcomes). Ensuring AI is deployed equitably and in a manner that improves health outcomes or, if improving efficiency of health care delivery, does so safely, requires progress in 4 areas. First, multistakeholder engagement throughout the total product life cycle is needed. This effort would include greater partnership of end users with developers in initial tool creation and greater partnership of developers, regulators, and health care systems in the evaluation of tools as they are deployed. Second, measurement tools for evaluation and monitoring should be developed and disseminated. Beyond proposed monitoring and certification initiatives, this will require new methods and expertise to allow health care systems to conduct or participate in rapid, efficient, and robust evaluations of effectiveness. The third priority is creation of a nationally representative data infrastructure and learning environment to support the generation of generalizable knowledge about health effects of AI tools across different settings. Fourth, an incentive structure should be promoted, using market forces and policy levers, to drive these changes. Conclusions and Relevance AI will disrupt every part of health and health care delivery in the coming years. Given the many long-standing problems in health care, this disruption represents an incredible opportunity. However, the odds that this disruption will improve health for all will depend heavily on the creation of an ecosystem capable of rapid, efficient, robust, and generalizable knowledge about the consequences of these tools on health.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信